SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients. Presently, we showed that the activation of ERK pathway was an important mechanis...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis Group
2023-12-01
|
| Reeks: | Cancer Biology & Therapy |
| Onderwerpen: | |
| Online toegang: | http://dx.doi.org/10.1080/15384047.2023.2206362 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|